HCPCS Level II drug code
J9035 — Injection, bevacizumab, 10 mg
In short
J9035 is the HCPCS Level II code for injection, bevacizumab, 10 mg. CMS assigns NDCs for Avastin to it. One billing unit is 10 mg. The Medicare Part B payment limit is $75.492 per unit (October 1, 2026 through December 31, 2026).
Code
Med-Code curated- Descriptor
- Injection, bevacizumab, 10 mg
- Code set
- HCPCS Level II, maintained by CMS
- Category
- Chemotherapy / VEGF Biologic
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 10 mg. For example, 1000 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Drugs mapped to J9035
FDA-listed products billed under J9035
Finished products in the FDA NDC Directory whose brand or single active ingredient, and route, match this code’s entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Alymsysbevacizumab-maly | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1754 |
| Alymsysbevacizumab-maly | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1755 |
| Avastinbevacizumab | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-060 |
| Avastinbevacizumab | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-061 |
| Mvasibevacizumab-awwb | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-206 |
| Mvasibevacizumab-awwb | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-207 |
| Vegzelmabevacizumab-adcd | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | CELLTRION USA, Inc. | 72606-011 |
| Vegzelmabevacizumab-adcd | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | CELLTRION USA, Inc. | 72606-012 |
| Zirabevbevacizumab-bvzr | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0315 |
| Zirabevbevacizumab-bvzr | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0342 |
All NDCs for these drugs
NDCs billed under J9035
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9035 for Avastin. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Avastin | 50242-0060-01 | Genentech, Inc. | 4 | 10 |
| Avastin | 50242-0061-01 | Genentech, Inc. | 16 | 40 |
J9035: common questions
- Is J9035 a CPT code?
- No. J9035 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J9035?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 2 NDCs under J9035, for Avastin. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J9035?
- $75.492 per 10 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J9035?
- One unit of J9035 is 10 mg, as stated in the code's descriptor. Units to report = dose given ÷ 10 mg. J-code billing units.